Noncontrolling Interest (Tables)

9 Months Ended

Sep. 30, 2024

Noncontrolling Interest [Abstract]

Schedule of Noncontrolling Interest of Stockholders' Equity

The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is summarized for the periods indicated as follows:

	September 30, 2024
NCI – equity - December 31, 2023	$	29,813
Net loss attributable to NCI		(11,075	)
Impact of subsidiary equity transactions		(4,414	)
Lucid Diagnostics proceeds from issuance of preferred stock Series A-1		5,670
Lucid Diagnostics exchange of preferred stock Series A and Series A-1		(24,294	)
Lucid Diagnostics issuance through exchange - Series B and Series B-1		31,790
Lucid Diagnostics issuance through sale - Series B and Series B-1		24,129
Lucid Diagnostics deemed dividend on preferred stock		(7,496	)
Lucid Diagnostics issuance of common stock for settlement of vendor service agreement		401
Lucid Diagnostics 2018 Equity Plan stock option exercise		4
Lucid Diagnostics Employee Stock Purchase Plan Purchase		353
Conversion of Lucid Diagnostics common stock for Senior Secured Convertible Debt		3,801
Stock-based compensation expense - Lucid Diagnostics 2018 Equity Plan		2,771
Stock-based compensation expense - Veris Health 2021 Equity Plan		368
Deconsolidation of Lucid		(56,339	)
NCI – equity - September 30, 2024	$	(4,518	)

Schedule of Net Loss Attributable to Common Stockholders

Lucid Series B Convertible Preferred Stock Issuance and Series A/A-1 Exchange Offer	March 13, 2024
Fair Value - 31,790 shares of Lucid Series B Preferred Stock issued in exchange for Lucid Series A and Lucid Series A-1 Preferred Stock	$	31,790
Less: Carrying value related to Lucid Series A and Lucid Series A-1 Preferred Stock Exchanged for Lucid Series B Preferred Stock (of 24,295 shares)		(24,294	)
Deemed Dividend Charged to Accumulated Deficit	$	7,496